Effectiveness of injectable extended-release naltrexone vs daily buprenorphine–naloxone for opioid dependence: a randomized clinical noninferiority trial. by unknown
Send email for updates
your.email@address  
 About updates
Key points 
From summary and commentary
A novel study testing the relative
effectiveness of injections of extended-
release naltrexone and a daily combination
of oral buprenorphine hydrochloride and
naloxone hydrochloride for maintaining
abstinence from heroin and other opioids.
Treatment with extended-release
naltrexone was found no less effective
than buprenorphine–naloxone in terms of
retaining patients in treatment, reducing
the number of days of injecting and
craving for opioids, and reducing the use
of heroin, and other illicit drugs.
The authors concluded that maintaining
short-term abstinence with extended-
release naltrexone should be considered
an “equal” medication-assisted treatment
alternative to buprenorphine-naloxone for
opioid-dependent individuals.
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Can monthly injections of extended-release naltrexone be considered on a par with the standard
daily opioid substitute in Norway for people wanting to maintain abstinence from heroin?
SUMMARY The featured study tested whether among recently withdrawn opiate-dependent
patients, injections of extended-release naltrexone were no less effective at maintaining
abstinence from heroin and other illicit drugs than the standard treatment for opiate dependence
in Norway, substitute prescribing of oral buprenorphine–naloxone on a maintenance basis. If no
less effective, the injections offer some advantages which may make them preferable. Lasting up
to a month, they block the effects of opiates and are not themselves an ‘abusable’ drug and do
not require frequent attendance at the clinic for supervised consumption of medication.
Participants were recruited through five urban
addiction centres in Norway from 1 November 2012
to 10 July 2015. All opioid dependent adults aged
18 to 60 years old who were attending outpatient
clinics and medically-supervised withdrawal units
were considered for the study. Other forms of drug
or alcohol dependence, or serious illnesses and/or
their treatments incompatible with the study’s
treatments, precluded people from participating.
Interviews were conducted with participants at the
start of the study, and then again every four
weeks. All participants (159) were required to go
through the process of withdrawal, before being
randomly allocated to receive either extended-
release naltrexone hydrochloride (380mg) injected
directly into the muscle every four weeks for 12
weeks, or a daily oral dose of buprenorphine–
naloxone (a flexible dose of 4–24mg per day).
Following the initial phase of treatment (known as
‘induction’), participants were also asked to attend
standard drug counselling.
The relative safety of the treatments was assessed
by comparing reports of adverse events. The
primary outcomes of the study were: retention;
proportion of urine samples testing negative for illicit opioids; and number of days using heroin
and other illicit opioids. Secondary outcomes were: number of days using cannabis,
amphetamines, cocaine, benzodiazepines, hallucinogens, and alcohol; number of days of
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injecting drugs; degree of heroin craving; thoughts about heroin; life satisfaction; satisfaction
with treatment; and mental health.
Main findings
Adverse events
More adverse events were reported in the extended-release naltrexone group than the
buprenorphine–naloxone group (69% vs. 35%). A number of these were related to symptoms of
withdrawal such as nausea, chills, shivering, diarrhoea, and sneezing, and again were more
frequent among the extended-release naltrexone participants (39% vs. 14%). Six participants
from the extended-release naltrexone group and three buprenorphine–naloxone participants
reported a serious adverse event. There were no dropouts among these participants – all
recovered completely and maintained their study medication. A total of 10 participants
discontinued treatment owing to adverse events: four in the extended-release naltrexone group,
and six in the buprenorphine–naloxone group.
Primary outcomes
Against all three primary outcomes, extended-release naloxone was found to be “noninferior” to
buprenorphine–naloxone [meaning that it wasn’t substantially (or it was no more than 20%)
worse than buprenorphine–naloxone.] When the researchers assessed whether one treatment
was better than the other they found that extended-release naltrexone participants had used
heroin significantly less often at all time points and other illicit opioids less often at the four- and
eight-week follow-ups.
Retention The average number of days participants received extended-release naltrexone and
buprenorphine–naloxone for before discontinuing was similar (69 and 63 days respectively).
After 12 weeks, 105 (66%) participants had attended all scheduled follow-up appointments and
taken their medication as prescribed, and 53 stopped participating (24 in the extended-release
naltrexone group and 29 in the buprenorphine–naloxone group). Of the 80 participants randomly
allocated to receive extended-release naltrexone, 56 completed 12 weeks of treatment, while 49
of the 79 receiving buprenorphine–naloxone completed 12 weeks of treatment.
Urine drug tests The proportion of urine samples testing negative for opioids was similar in the
extended-release naltrexone and buprenorphine–naloxone groups (average of 80% and 90%
respectively).
Use of heroin and other illicit opioids Extended-release naltrexone participants used
significantly less heroin at all time points and less of other illicit opioids at weeks four and eight.
The average difference in number of days of use of heroin and other illicit opioids was not
substantially lower in the extended-release naltrexone group compared with the buprenorphine–
naloxone group.
Secondary outcomes
Injecting and use of other drugs There were no significant differences between the treatment
groups in the pattern of use of amphetamines, cocaine, alcohol, cannabis, or injecting drugs.
However, participants receiving extended-release naltrexone had a significant reduction in days
of benzodiazepine use, while the buprenorphine naloxone group remained stable. There were no
significant differences between groups at different time points. Hallucinogens were used once or
twice by five participants receiving extended-release naltrexone and four receiving
buprenorphine naloxone.
Craving and thoughts about heroin At all time points, participants receiving extended-
release naltrexone reported significantly less heroin craving and thoughts about heroin than
buprenorphine–naloxone participants.
Life satisfaction Life satisfaction was significantly higher among extended-release naltrexone
participants at weeks four and eight, but not at week 12.
Satisfaction with treatment Satisfaction with treatment was significantly higher among
extended-release naltrexone participants, who were also more likely to recommend their
treatment to others compared with buprenorphine–naloxone participants.
Mental health There was no significant difference between the groups in terms of mental health
symptoms.
The authors’ conclusions
Treatment with extended-release naltrexone was found to be no less effective than
buprenorphine–naloxone in retaining patients in treatment, reducing the number of days of
injecting and craving for opioids, and reducing the use of heroin, and other illicit drugs.
The main clinical implication of the findings was that extended-release naltrexone seems to be
as safe as, and no less effective than, buprenorphine–naloxone for patients wanting to maintain
abstinence from heroin and other opioids in the short-term, and therefore should be an available
treatment option. This applies specifically to opioid-dependent individuals who have recently
gone through the process of withdrawal and/or recently been discharged from inpatient
treatment or prison, but may also be relevant to the growing number of people addicted to
prescription opioids.
 
 COMMENTARY To the authors’ knowledge, this was the first study to compare the
effectiveness of extended-release naltrexone with a daily combination of buprenorphine and
naloxone, the standard opioid medication treatment in Norway (the country the study was
conducted in).
Extended-release naltrexone and buprenorphine–naloxone are radically different treatments
intended for different purposes and different types of patients. They differ not only in the way
that they are taken (injected vs. oral), and the frequency of use (roughly monthly vs. daily), but
in the pharmacological effects of the drugs themselves: 
• Naltrexone promotes abstinence from all opioids by ‘forcing’ a life free of the effects of these
drugs. 
• Buprenorphine–naloxone meanwhile provides a legal opiate substitute for patients who want to
or feel they have to continue to experience and rely on these drugs, but more safely.
The featured study judged “extended-release naltrexone … as effective as buprenorphine–
naloxone in maintaining short-term abstinence from heroin and other illicit substances”. The
basis for the findings was a “noninferiority trial”: a type of trial that seeks to “demonstrate that
an experimental treatment is not substantially worse than … [an established] treatment”.
Breaking down the meaning and implications of non-inferiority trials, one paper explains that
“With continuous improvements in health technologies, standard care, and clinical outcomes, the
incremental benefits of newly developed treatments may be only marginal over existing
treatments”, and so what non-inferiority trials do is (initially) lower the bar for proof of
effectiveness in order for new treatments to be brought into the field, established, and further
tested. In guidelines for the reporting of such trials, the Consolidated Standards of Reporting
Trials (CONSORT) Group acknowledged the frequent use of non-inferiority trials “because of the
need to replace standard treatments by other treatments having comparable efficacy but
presenting other advantages” (emphasis added). The featured paper highlighted some of the
“other advantages” of extended-release naltrexone, which included better opportunities for
creating a life, routine, and identity (for example through returning to work or education) when
not having to meet daily or every second day for supervised intake of medication. This, as the
authors pointed out, may help to explain why both satisfaction with treatment and willingness to
recommend their treatment to others were significantly higher among extended-release
naltrexone participants. Another factor was likely the novelty of extended-release naltrexone –
versus buprenorphine–naloxone which was widely available in Norway – giving participants the
added motivation to try an ‘alternative’ treatment. Participants were also more typical of a
naltrexone caseload than a standard substitute prescribing caseload, as they were all
(presumably) abstinent at the start of treatment – having been “discharged from detoxification
units, inpatient treatment, or prison” and having gone through the process of withdrawal.
Non-inferiority trials do not feature a control group – a group receiving no intervention or none
relevant to the outcomes being assessed. While this falls short of the rigour of ‘gold standard’
randomised controlled trials, non-inferiority trials are often used when withholding available
treatments would have serious outcomes (eg, risk of mortality) for patients. Regardless of the
rationale there are implications for the interpretation of findings from non-inferiority trials. The
main point is that without a control group it is not possible to assume that any observed effects
can be attributed to the treatment of interest (in this case extended-release naltrexone).
Typically in studies which test whether one treatment is superior to another treatment (or no
treatment), performing the analysis on an ‘intention to treat’ sample is the most conservative
approach – including all participants who were randomised in the study, regardless of whether
they received the treatment or not. However it is not necessarily the most conservative
approach in non-inferiority trials as “including dropouts in the analysis tends to bias the results
toward [a finding of] equivalence”. The recommended approach for non-inferiority trials is to
perform intention to treat analysis along with something called ‘per-protocol’ analysis (including
all patients who satisfactorily complied with the assigned treatment), and to only conclude non-
inferiority if both analyses produce the same result. The featured paper only reports that an
intention to treat analysis was conducted, which the above suggests would not be as cautiously
moderate as recommended for this type of (non-inferiority) trial. However, it may be that an
intention to treat analysis wasn’t conducted anyway – or at least wasn’t the only analysis
conducted. When the paper described the number of participants included in the analysis (see
Figure 1), it referred to 56 extended-release naltrexone and 49 buprenorphine–naloxone
participants who completed 12 weeks of treatment (ie, the per-protocol sample), not the 80
extended-release naltrexone and 79 buprenorphine–naloxone participants initially randomised
(ie, the intention to treat sample). To further complicate matters, the original protocol declared
that the data would be analysed with a ‘modified intention to treat’ sample (a subset of the
intention to treat sample, in this case including all randomised patients who received at least
one dose of study treatment and who had at least one valid assessment), whereas the more
recent protocol, published a year before the study, specified that intention to treat analysis
would be performed, and “depending on publication requirements”, different analyses would also
be conducted.
The clinical interpretation of the findings was that “maintaining short-term opioid abstinence
with extended-release naltrexone should be considered an equal treatment alternative to
buprenorphine–naloxone as medication-assisted treatment for opioid-dependent individuals”
(emphasis added). The word equal implied equivalence, but the trial wasn’t strictly a test of
equivalence; it was a test to see that the new treatment wasn’t worse than the established
treatment “by more than an acceptable amount” (known as the ‘margin of difference’). This
detail helps in understanding the implications of the findings.
It’s recommended that the margin of difference be “prospectively defined” – in other words,
decided and declared before the data has been collected and analysed (1 2). In the featured
study it was unclear whether the 20% margin was indeed pre-set because while it was reported
in the 2016 protocol (the year before the featured paper was published), it was not in the
original 2012 protocol. Furthermore there was no explanation of how the margin was
determined. These traits in reporting are not uncommon in non-inferiority and equivalence trials,
leading the CONSORT group to report that “the quality of reports of noninferiority and
equivalence trials remains poor”. In one review, for example, only about a fifth of 332 non-
inferiority and equivalence trials between 1990 to 2000 provided a suitable rationale for the
margin of difference, and in another review, almost all 232 reports of noninferiority and
equivalence trials specified the margin of difference, but only 24% explained how it was
determined (1 2).
A unique study published in the The Lancet journal tested what would happen if heroin
dependent patients in Malaysia who had been through the process of withdrawal were
maintained on a substitute drug, on an opiate-blocking medication, or simply counselled. At the
time naltrexone was the main long-term pharmacotherapy and maintenance substitute
prescribing was not permitted, but the results – oral naltrexone offered no substantial
advantages, but substitute prescribing made a big difference to how long and how many patients
were able to live without regular resort to illegal opiates – led to the introduction of methadone
prescribing programmes.
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